HHS proposes letting pharmacies make peptides
- HHS quietly sends a plan to the White House that would let compounding pharmacies churn out six trendy peptides, skipping the FDA's clinical trial dog-and-pony show.
- The FDA's own staff warned these peptides are unproven and potentially dangerous—tumor growth, contamination, allergic reactions—but a panel stacked with six members who *sell* the stuff voted yes anyway.
- RFK Jr. argues Americans are buying 'gray market' Chinese peptides, so the feds should just legitimize the gray market here instead of, you know, regulating it.
- Peptide in question BPC-157 is a gym-bro favorite for 'muscle building and injury recovery,' despite zero FDA approval for human use and a CVS receipt's worth of untested side effects.
Brief Summary
In a move that screams 'disruption' more than 'public health,' the Department of Health and Human Services is pushing to let your local corner pharmacy brew up boutique peptides like BPC-157, the trendy muscle-mending molecule that's all the rage among biohackers and podcast bros. The proposal follows a July FDA advisory panel that recommended loosening the leash on six of seven peptides—a panel that, conveniently, included eight recent Kennedy appointees, six of whom run or work at clinics hawking these exact potions. That's not a conflict of interest; that's a business model.
Why This Matters
This matters to you because the next time you walk into a compounding pharmacy for a mundane allergy shot, the guy in the back might also be whipping up a batch of untested 'longevity' peptides that could, per the FDA's own staff, promote tumor growth or trigger an allergic meltdown. The policy is being fast-tracked through the White House with no public comment on which substances will be legal, meaning your 'health freedom' might come with a side of unintended biological consequences.